IP Abuses Hold Back European Market
White Paper Highlights How Inappropriate Use Of IP Is Restricting Access
A report on intellectual property barriers to generics and biosimilars in Europe sets out some key recommendations on how to address originator strategies and abuses in this area.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.